Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Applied Digital | Qualcomm | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | narrow Qualcomm's advantage is real but concentrated in one segment. The FY2025 10-K (filed 2025-11-05) describes its portfolio as "the most widely and extensively licensed in the industry" and says the industry "generally recognizes that any company seeking to develop, manufacture and/or sell certain cellular products requires a license or other rights to use our patents". That licensing leg produced $5,582M of FY2025 revenue against $38,367M at QCT, where Apple, Samsung and Xiaomi are all named in the vertical-integration risk factor and Apple already "utilizes its own modem... in certain of its smartphones". The filing frames the QCT loss as expected rather than realised. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | intangibles ip The durable asset is intellectual property accumulated since Qualcomm's founding "in 1985". The patents have "broad coverage in many countries, including Brazil, China, India, Japan, South Korea, Taiwan, the United States and countries in Europe" and are licensed "to hundreds of companies on industry-accepted terms", with royalties set as "a percentage of the wholesale (i.e., licensee's) selling price... subject to per unit minimums and/or per unit caps". R&D of $9,042M equalled 20% of revenues. Manufacturing is fabless "other than for certain of our RFFE modules and RF filter products", for which Qualcomm owns fabs in Germany and Singapore. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | co leader Leadership is clear in licensing and contested in silicon. The 10-K names no rival licensing programme and asserts the portfolio is "the most widely and extensively licensed in the industry", while calling QCT's industries "intensely competitive" and naming eleven competitors (Broadcom, HiSilicon, MediaTek, Mobileye, Nvidia, NXP, Qorvo, Samsung, Skyworks, TI, UNISOC); "continue to be a leader in mobile" appears in a list of things future success depends on, so it reads as aspiration, not share. The band therefore rests on the licensing leg, roughly 13% of revenue. FY2025 10%-plus customers were 21%, 20% and 13%; in 9M FY2026 only two cleared 10%. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | moderate QTL margins held at 72% in FY2025 and 73% in 9M FY2026, though Q3 FY2026 alone slipped to 69% from 71%, and the $111M revenue gain there is attributed to revenues per unit "primarily driven by favorable mix" rather than to price. At QCT, the fall to 26% from 30% is explained by "lower gross margin, primarily driven by higher product cost, partially offset by higher average selling prices" plus lower revenues, so the pressure is cost rather than price; FY2025 handsets rose $2,930M, of which $2.5B came from higher revenue per chipset. Against that, "declining average selling prices" is a standing risk-factor title, "particularly pronounced in emerging regions and China". |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | Qualcomm has two legs pointing in opposite directions. QTL (FY2025 revenue $5,582M, EBT margin 72%) rests on a portfolio the 10-K calls "the most widely and extensively licensed in the industry", with royalties struck on the licensee's wholesale device price under per-unit minimums and caps; its durability is dated in the filing, since "our patent license agreements with key OEMs are generally long-term, with terms expiring at varying dates between fiscal 2027 and 2031", some with binding-arbitration renewal clauses, and Huawei's licence has already expired, removing its royalties from QTL revenue from Q2 FY2025. QCT ($38,367M, 87% of segment revenue) is the leg under pressure: its three 10%-plus customers all build their own silicon, Apple already ships its own modem, and QCT EBT margin fell to 26% in Q3 FY2026 from 30%. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | Every figure and quotation is drawn from the FY2025 10-K and the Q3 FY2026 10-Q. Where the filings state no market share, the share band is left unknown rather than inferred, and barrier bands follow the filings' own language, which states a barrier to entry only for automotive. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm bearish Editorial prior, not backtested. |